Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
9.25 ^USD	+2.10%		-1.18%	-34.07%

15/05	Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	CI
08/05	Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Peter Kushner, Chief Scientific Officer of Olema Pharmaceuticals, Inc. Announces Transition from CSO to Senior Research Fellow and Co-Founder, A Non-Executive Role, Effective April 1, 2022

March 15, 2022 at 02:17 am IST

On March 10, 2022, Peter Kushner, Ph.D., Chief Scientific Officer of Olema Pharmaceuticals, Inc. and the Company agreed that Dr. Kushner would transition from CSO to Senior Research Fellow and Co-Founder, a non-executive role, effective April 1, 2022.

Latest news about Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	15/05	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target	02/04	MT
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	18/03	CI
HC Wainwright Adjusts Price Target on Olema Pharmaceuticals to $25 From $28, Maintains Buy Rating	12/03	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	06/03	CI
Citigroup Initiates Olema Pharmaceuticals at Buy With $20 Price Target	30/01	MT
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01	CI
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	18/12	CI
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	05/12	CI
Transcript : Olema Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 01:20 PM	29/11
Olema Pharmaceuticals Insider Sold Shares Worth $269,656, According to a Recent SEC Filing	24/11	MT
Olema Pharmaceuticals Insider Sold Shares Worth $824,134, According to a Recent SEC Filing	24/11	MT
Olema Pharmaceuticals Insider Sold Shares Worth $196,233, According to a Recent SEC Filing	24/11	MT
Olema Pharmaceuticals Insider Sold Shares Worth $209,296, According to a Recent SEC Filing	24/11	MT
Olema Pharmaceuticals Insider Sold Shares Worth $117,740, According to a Recent SEC Filing	24/11	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Olema Pharmaceuticals Insider Sold Shares Worth $379,450, According to a Recent SEC Filing	03/11	MT
JPMorgan Adjusts Olema Pharmaceuticals' Price Target to $25 From $19, Maintains Overweight Rating	24/23/24	MT
Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating	24/23/24	MT
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant	23/23/23	CI
Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors	17/23/17	CI
Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress	16/23/16	CI

Chart Olema Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - American Society of Clinical Oncology Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.25 USD

Average target price

26.56 USD

Spread / Average Target

+187.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OLEMA PHARMACEUTICALS, INC.	-34.07%	517M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+37.60%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research